These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 10351157)
21. Blood supplies hit by vCJD fear. Strachan-Bennett S Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624 [No Abstract] [Full Text] [Related]
22. Leukocyte reduction of blood components: public policy and new technology. Dzik S; Aubuchon J; Jeffries L; Kleinman S; Manno C; Murphy MF; Popovsky MA; Sayers M; Silberstein LE; Slichter SJ; Vamvakas EC Transfus Med Rev; 2000 Jan; 14(1):34-52. PubMed ID: 10669939 [No Abstract] [Full Text] [Related]
23. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force. Transfus Med; 1998 Mar; 8(1):59-71. PubMed ID: 9569462 [No Abstract] [Full Text] [Related]
32. Universal leukodepletion of blood and febrile transfusion reactions. Rennie I; Rawlinson PS; Clark P Transfus Med; 2001 Apr; 11(2):115. PubMed ID: 11299029 [No Abstract] [Full Text] [Related]
33. National French observatory of the quality of blood components for transfusion. Chabanel A; Masse M; Begue S; Transfus Clin Biol; 2008 Jun; 15(3):85-90. PubMed ID: 18524661 [TBL] [Abstract][Full Text] [Related]
34. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment. Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902 [TBL] [Abstract][Full Text] [Related]
35. Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views. Seghatchian J Transfus Apher Sci; 2015 Apr; 52(2):233-6. PubMed ID: 25748230 [TBL] [Abstract][Full Text] [Related]
36. Under pressure. Siddall R Health Serv J; 2003 Aug; 113(5869):12-3. PubMed ID: 12953390 [No Abstract] [Full Text] [Related]
37. Variant Creutzfeldt-Jakob disease and prions in the blood supply. Rohwer RG; Drohan W Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166 [No Abstract] [Full Text] [Related]
38. Quality control of leucoreduced cellular blood components in France. Chabanel A; Andreu G; Carrat F; Hervé P Vox Sang; 2002 Feb; 82(2):67-71. PubMed ID: 11906669 [TBL] [Abstract][Full Text] [Related]
39. Japan plans blood-donor restrictions to combat vCJD. Fuyuno I Nature; 2005 Mar; 434(7031):260. PubMed ID: 15772611 [No Abstract] [Full Text] [Related]
40. Universal leucodepletion to reduce potential risk of transmission of new-variant Creutzfeld-Jakob disease. Turner M Br J Haematol; 2000 Sep; 110(3):745-8. PubMed ID: 10997991 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]